DrugPatentWatch Database Preview
saxenda Drug Profile
Which patents cover Saxenda, and what generic alternatives are available?
Saxenda is a drug marketed by Novo and is included in one NDA. There are nineteen patents protecting this drug.
This drug has two hundred and fifty-eight patent family members in twenty-seven countries.
The generic ingredient in SAXENDA is liraglutide recombinant. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the liraglutide recombinant profile page.
Summary for saxenda
| International Patents: | 258 |
| US Patents: | 19 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 2 |
| Clinical Trials: | 21 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for saxenda |
| Drug Sales Revenues: | Drug sales revenues for saxenda |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for saxenda |
| Prior Art and Litigation Support | Order Prior Art and Litigation support for saxenda |
| DailyMed Link: | saxenda at DailyMed |
Pharmacology for saxenda
| Drug Class | GLP-1 Receptor Agonist |
| Mechanism of Action | Glucagon-like Peptide-1 (GLP-1) Agonists |
Medical Subject Heading (MeSH) Categories for saxenda
US Patents and Regulatory Information for saxenda
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for saxenda
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | ➤ Sign Up | ➤ Sign Up |
| Novo | SAXENDA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 206321-001 | Dec 23, 2014 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for saxenda
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 3300721 | ➤ Sign Up |
| European Patent Office | 2394656 | ➤ Sign Up |
| Germany | 60328927 | ➤ Sign Up |
| Japan | 2012051894 | ➤ Sign Up |
| Denmark | 1819382 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 9943361 | ➤ Sign Up |
| Norway | 325273 | ➤ Sign Up |
| Country | Patent Number | Estimated Expiration |
Supplementary Protection Certificates for saxenda
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2209800 | C02209800/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: INSULIN DEGLUDEC + LIRAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC 65041 12.09.2014 |
| 0944648 | C00944648/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: LIRAGLUTID; REGISTRATION NO/DATE: SWISSMEDIC 59329 11.12.2009 |
| 2209800 | 122014000114 | Germany | ➤ Sign Up | PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
| 2209800 | 14C0085 | France | ➤ Sign Up | PRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
| 0944648 | CA 2009 00041 | Denmark | ➤ Sign Up | |
| 0944648 | SPC/GB09/058 | United Kingdom | ➤ Sign Up | PRODUCT NAME: LIRAGLUTIDE; REGISTERED: UK EU/1/09/529/001 20090630 |
| 2209800 | C300698 | Netherlands | ➤ Sign Up | PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918 |
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
